The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, ...

Hutchmed (HCM) stock rises despite a 2024 revenue miss as a cancer drug combo it developed with Innovent Biologics (IVBYI) ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Advanced treatments for kidney failure offers patients improved survival rates and quality of life. Discover the options from ...

Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory ...

Genenta announced a EUR 20M financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical to support the expansion ...

Chinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...

(Alliance News) - Hutchmed China Ltd on Wednesday hailed results of a clinical trial evaluating its kidney cancer treatment in China, while it reported an annual revenue dive. The Hong Kong-based ...

The following is a summary of “Lipid abnormality in diabetic kidney disease and potential treatment advancements,” published ...

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

Patanjali’s Renogrit effectively mitigates kidney damage caused by the cancer drug cisplatin, according to a study published ...